James Crowe

December 10, 2020

Exploiting viral vulnerabilities

The isolation of human monoclonal antibodies against dangerous viruses including EEEV, Hendra and Nipah could offer new ways to treat and prevent these infections.

James Crowe Jr., MD, and colleagues are exploring how the body’s immune system gears up to fight off infection.
December 1, 2020

Vanderbilt University Medical Center’s Crowe receives 2020 “Golden Goose” Award for COVID-19 research

James Crowe Jr., MD, a physician-scientist at Vanderbilt University Medical Center who has pioneered development of human monoclonal antibodies as potential treatments for viral diseases, has won a 2020 “Golden Goose” Award.

October 29, 2020

VUMC’s resilience amid COVID: Caring for ourselves as we care for others

Caring for ourselves and for one another will be fundamental to the people of Vanderbilt University Medical Center in the coming weeks as COVID-19 is surging, and over the year as the enterprise adapts further to changes while expanding locally and regionally.

James Crowe Jr., MD, and colleagues are exploring how the body’s immune system gears up to fight off infection.
October 13, 2020

COVID-19 long-acting antibodies discovered by Vanderbilt University Medical Center move to phase 3 clinical trials

AstraZeneca is advancing into phase 3 clinical trials with an investigational COVID-19 therapy of two long-acting antibodies discovered by Vanderbilt University Medical Center and optimized by AstraZeneca.

Lab manager Rachel Nargi prepares a B-cell culture during the recent “sprint” to develop an antibody-based treatment for Zika virus infection.
August 20, 2020

Study identifies antibodies that block alphaviruses

Researchers at Vanderbilt University Medical Center have identified antibodies that, in animals, block infection by alphaviruses, which can cause chronic and debilitating joint pain and arthritis and are an increasing global health concern.

July 15, 2020

Antibody research at Vanderbilt University Medical Center shows promise in fight against COVID-19

Based on positive results in preclinical studies reported today, potently neutralizing antibodies identified by researchers at Vanderbilt University Medical Center are showing promise as a potential therapy for preventing and treating COVID-19.